Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
MEGF9 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P, WB, E |
|---|---|
| Primary Accession | Q9H1U4 |
| Other Accession | Q8BH27, NP_001073966.2 |
| Reactivity | Human |
| Predicted | Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 62984 Da |
| Antigen Region | 521-549 aa |
| Gene ID | 1955 |
|---|---|
| Other Names | Multiple epidermal growth factor-like domains protein 9, Multiple EGF-like domains protein 9, Epidermal growth factor-like protein 5, EGF-like protein 5, MEGF9, EGFL5, KIAA0818 |
| Target/Specificity | This MEGF9 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 521-549 amino acids from the C-terminal region of human MEGF9. |
| Dilution | WB~~1:1000 IHC-P~~1:10~50 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | MEGF9 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | MEGF9 |
|---|---|
| Synonyms | EGFL5, KIAA0818 |
| Cellular Location | Membrane; Single-pass type I membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
MEGF9 (multiple EGF-like-domains 9) is a novel transmembrane protein with multiple EGF-like repeats, which is predominantly expressed in the developing and adult CNS (central nervous system) and PNS (peripheral nervous system). The domain structure of MEGF9 consists of an N-terminal region with several potential O-glycosylation sites followed by five EGF-like domains, which are highly homologous with the short arms of laminins. Following one single pass transmembrane domain, a highly conserved short intracellular domain with potential phosphorylation sites is present.
References
Barber, M.J., et al. PLoS ONE 5 (3), E9763 (2010) :
Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003)
Nakayama, M., et al. Genomics 51(1):27-34(1998)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
